• Neuralstem Inc., of Rockville, Md., dosed its first patient in a trial of a stem cell therapy in the cervical region of the spine in an ongoing safety trial in amyotrophic lateral sclerosis. The previous 12 patients in the study received stem cell transplants in the lumbar region of the spine, but patient 13 received the transplant in the gray matter of the cervical region.